- Ensuring Pakistan's national health security
- Attracting USD 235 million foreign direct investment to Pakistan
AsiaPak investments is the first company in Pakistan to pioneer this initiative, demonstrating leadership in advancing plasma-based therapies. Their efforts will bridge a critical gap in the healthcare supply chain, and position Pakistan as a regional leader in bio-pharmaceutical innovation.
AsiaPak Investments is a diversified company with proven track record in Pakistan of successful partnerships with leading Chinese companies.
AsiaPak portfolio includes KE, Sino Sindh Resources (Thar Coal Block One), Liberty Power Daharki, Heavy Electrical Complex, Daewoo Express, Lotte Chemicals, and, BOL TV. AsiaPak’s partners include Shanghai Electric, NORINCO, and, Guanghzou Metro.
For this vital national health security initiative, AsiaPak has partnered with China Resources Boya Bio-Pharmaceutical Co., Ltd, a company with extensive experience, technica leadership, and, global expertise in the field of Plasma Collection and Plasma Derived Medicinal Products (PDMPs). Boya is a top 5 bio-pharmaceutical company in China with revenue in 2023 of USD 440 million and market capitalization of USD 2.5 billion.
Boya's parent company China Resources is one of the largest and most successful state owned conglomerates in China. It has a diverse business portfolio including energy/power, pharmaceuticals, food & beverage, real estate, retail, and, more. China Resources annual group revenues are USD 150 billion, and, it is ranked #72 in the Fortune Global 500.
“In the spirit of Iron Brothers, China Resources is honoured and enthusiastic to be bringing Chinese expertise and technology for saving precious lives in Pakistan. This is a win-win!” said Mr Kai Qiu, Chairman of China Resources Boya Bio-Pharmaceutical Group Special Investment Facilitation Council (SIFC) has facilitated and elevated this partnership between AsiaPak Investments and Chia Resources so that Pakistan's national security may be improved, while attracting foreign investment into Pakistan.
“We thank SIFC for their world-class professional support in facilitating our joint venture. As a result of SIFC efforts, we are together solving a critical problem – the lack of affordable lifesaving plasma based medicines in Pakistan. SIFC efforts are further proof that Pakistan is an attractive destination for foreign investors”, said Shaheryar Chishty, Founder and CEO of AsiaPak Investments.
AsiaPak and China Resources have signed a framework partnership with the following mutual commitments that will make Pakistan self-sufficient in plasma collection and in plasma derived medicines:
- Invest USD 25 million to build the first wave of plasma collection centers in
- Target launching the central hub in 2026 in Islamabad, comprising plasma collection, lab testing, storage, logistics, and, administrative functions
- Invest additional USD 210 million in building Pakistan’s only fractionation facility which will manufacture plasma derived medicines
- Create hundreds of high skilled jobs in Pakistan
- Explore export opportunity to regional markets
“We offer a special note of thanks for the Prime Minister's inspirational leadership in re-vitalizing Pakistan into an attractive investment destination for talented foreign and domestic investors”.
It was in Beijing 10 years ago that the Prime Minister's brother Mian Nawaz Sharif witnessed my brother Shaheryar Chishty, Founder and CEO of AsiaPak Investments, signing the partnership agreement between AsiaPak Investments and Shanghai Electric for developing the energy resources of Thar Coal Block One.
That partnership kicked off the China Pakistan Economic Corridor. Similarly, we pray today's agreement catalyzes the next wave of investment cooperation between our Iron Brother nations," said Chairman of AsiaPak Investments, Sameer Arshad Chishty.
The Ministry of National Health Services and Coordination paved the way for national plasma security by framing a progressive policy that allows for the regulated export of source plasma and import of essential PDMPs, ensuring a balanced approach to meet domestic needs while integrating Pakistan into the global biopharmaceutical market. By fostering local production, we can ensure affordability, accessibility, and quality care for patients while stimulating economic growth through investment in biotechnology.
“We thank Syed Mustafa Kamal for his vanguard role in collaboratively aligning all provinces and regulatory bodies”, said Brigadier (R) Doctor Ms. Nuzhat Mushahid, of AsiaPak Investments.
